RBC rates NeuroMetrix at outperform

RBC Capital Markets analyst William R. Quirk rated NeuroMetrix Inc. at outperform, speculative risk, as shares of the stock are off 41.6% since the second quarter conference call, largely on what the analyst considers unfounded concerns. The shares were hit hard toward the end of trading Wednesday on false news snippets from various services. RBC believes the two companies with competing nerve conduction devices do not have the supporting data, product labels or sales force required to successfully compete with NeuroMetrix. Shares of the Waltham, Mass.-based medical device company were up $2.51, or 13.39%, at $21.25. (Nasdaq: NURO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.